Navigation Links
Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
Date:5/10/2011

ment due to adverse reactions in the controlled clinical studies was 5% for certolizumab pegol and 2.5% for placebo.

Please see full prescribing information at www.cimzia.com before prescribing.

About CIMZIA®

Cimzia® is the only PEGylated anti-TNF (Tumor Necrosis Factor). Cimzia® has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation. This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. The U.S. Food and Drug Administration (FDA) has approved Cimzia® for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy and for the treatment of adults with moderately to severely active rheumatoid arthritis. Cimzia® in combination with MTX, is approved in the EU for the treatment of moderate to severe active RA in adult patients inadequately responsive to disease-modifying antirheumatic drugs (DMARDs) including MTX. Cimzia® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. UCB is also developing Cimzia® in other autoimmune disease indications. Cimzia® is a registered trademark of UCB PHARMA S.A.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9000 people in over 40 countries, UCB produced r
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
2. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
3. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
4. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
5. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
6. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
7. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
8. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
9. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
10. New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
11. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... 2015 PGI has announced an expansion of ... America at its San Luis ... plant expansion is centered on solving the challenge of ... for personal care product manufacturers. The ... slitting and packaging, will allow customers to take advantage ...
(Date:3/31/2015)... YORK , March 31, 2015 Immune ... announced today that it intends to expand its planned ... human monoclonal antibody targeting eotaxin-1. Bullous Pemphigoid is an ... 60,000 patients in the US and Europe ... to start enrolling patients in a Phase II clinical ...
(Date:3/31/2015)... , March 31, 2015   Unique Pharmaceuticals ... transformation is complete and the company has initiated sterile ... "Our goal as a company is to meet ... Travis Leeah . "Meeting the new regulations is validation ... We,re embracing the future of our industry, investing in ...
Breaking Medicine Technology:PGI Expands Manufacturing Capabilities At Mexico Plant 2Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 2Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 4Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 2Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 3
... NEW YORK, June 22, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0559270/US-Urinary-Incontinence-Devices.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Food_Ingredient ... the urinary incontinence device market. The urinary ...
... June 22, 2011 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: ... leading manufacturer of medical dressings, medical disposables and non-woven fabric ... the Company,s management team will present at the 2011 Brean ... held on June 27 and 28, 2011 at the JW ...
Cached Medicine Technology:Reportlinker Adds U.S. Urinary Incontinence Devices 2Reportlinker Adds U.S. Urinary Incontinence Devices 3Reportlinker Adds U.S. Urinary Incontinence Devices 4Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 2Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 3
(Date:3/31/2015)... (PRWEB) March 31, 2015 Simeon Boyd, ... a nearly $4 million, five-year grant from the National ... team of physicians and scientists from more than 10 ... including Australia, Brazil, Bulgaria, Germany, Hungary, Italy and the ... the bony plates of the skull in infants. , ...
(Date:3/31/2015)... Indosoft, developer of the Q-Suite call center software suite, ... their 5.x line. The industry leading contact center ACD ... world for more than a decade. By announcing an end ... can fully embrace newer Asterisk features and improve performance. , ... for more than a decade. The use of Asterisk, a ...
(Date:3/31/2015)... On March 26, 2015, Vogue Magazine UK, ... Slope?” provides a look into the trend of young women ... laser treatments . The article suggests that celebrity endorsements (Beyoncé ... as Kim Kardashian and Kylie Jenner are the drivers behind ... as significant influences on the self-esteem of teenagers. (see: goo.gl/NmaB4q) ...
(Date:3/31/2015)... March 31, 2015 Dr. ... by the American Board of Dermatology and fellowship ... research training at the National Cancer Institute of ... his internship in internal medicine at the Emory ... Pennsylvania in Philadelphia. Dr. Li pursued further training ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 At Summit Breast ... all patients in a calm and caring manner. , Summit ... diagnosis and surgical treatment of breast cancer. They treat ... but from all over the world. Their doctors continue ... publications. , The seeds for Summit Breast Care were planted ...
Breaking Medicine News(10 mins):Health News:International team of researchers led by UC Davis receives $4 million NIH grant to study skull disorder in infants 2Health News:International team of researchers led by UC Davis receives $4 million NIH grant to study skull disorder in infants 3Health News:Indosoft Announces End of Life for Asterisk 1.4 Support in Q-Suite 5 Call Center Software 2Health News:Cosmetic Surgery: Does Social Media Pressure Young Girls to Get Botox and Fillers? 2Health News:Dr. Andrew Li of Warren Skin Care Center Is Celebrating 3 Years Recognized as an "NJ Top Doc" 2Health News:Summit Breast Care is Celebrating Four Years as "NJ Top Docs" 2
... in liver, which may trigger disease, study says , , FRIDAY, ... to play a role in insulin resistance that can be ... sweetener found in most sodas and many processed foods. ... protected from insulin resistance when PGC-1b activity was blocked in ...
... The United States has intervened in a whistleblower suit filed ... Inc. (CHS) and three of its hospitals in New Mexico: ... in Deming, and Alta Vista Regional Hospital in Las Vegas. ... violated the False Claims Act (FCA) by knowingly causing to ...
... Concern Audit OpinionISELIN, N.J., March 6 Pharmos Corporation ... has received a Nasdaq Staff Determination that the company ... equity requirement for continued listing. Unless the company appeals ... and registration on The Nasdaq Stock Market. Pharmos does ...
... may affect diaphragm, chest wall to decrease volume, study ... big around the middle can put the squeeze on ... than 120,000 people. , It was already known that ... women and greater than 40 inches for men) was ...
... Donate Life - Texas Registry will be in front of the Capitol Grill ... p.m. educating people on the donor registration process and getting them signed up ... ... Glenda Dawson Donate Life - Texas Registry will be in front ...
... Massachusetts General Hospital (MGH) clinics indicated they would be willing ... have their daughters and even sons vaccinated in order to ... March issue of Gynecologic Oncology also found that ... to accept HPV vaccine as non-Latinos. , "Since ...
Cached Medicine News:Health News:Gene Explains How High-Fructose Diets Lead to Insulin Resistance 2Health News:United States Joins Suit Against Community Health Systems Inc. and Three of Its Hospitals in New Mexico 2Health News:Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination 2Health News:Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination 3Health News:Belly Fat Puts the Pressure on Lungs 2Health News:Donate Life Day at the Capitol to Increase Awareness for Organ Donation and Registration 2Health News:Donate Life Day at the Capitol to Increase Awareness for Organ Donation and Registration 3Health News:Donate Life Day at the Capitol to Increase Awareness for Organ Donation and Registration 4Health News:Both Latino and non-Latino women likely to accept HPV vaccination for selves and children 2Health News:Both Latino and non-Latino women likely to accept HPV vaccination for selves and children 3
Auto refractometer....
... most advanced automatic refractor/keratometer ... today. It adds the ... readings simultaneously. It also ... focusing, automatic tracking, automatic ...
... Laserex Tango ophthalmic laser system provides two ... laser and a photodisruptor for posterior capsulotomy ... frequency-doubled Nd:YAG producing pulsed 532 nm light. ... 1064 nm. The appropriate laser can be ...
Thin and smooth jaws, designed to enter trough 3 mm incision, cross action....
Medicine Products: